AstraZeneca Confirms Exploring Potential Strategic Options With Acerta Pharma

Further to recent speculation, AstraZeneca

confirms that it is exploring potential strategic options with Acerta Pharma BV. There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction. The Company will make a further announcement if and when appropriate.

first reported a potential deal between the companies on Friday. AstraZeneca shares closed down $0.22 on Friday, at $33.25.